The CDL Advanced Therapies Stream, hosted at the Rotman School of Management, University of Toronto, is part of Creative Destruction Lab’s Health domain and focuses on early-stage biotech ventures working on next-generation therapeutics. This highly selective program helps ventures working on modalities such as gene therapy, cell therapy, mRNA platforms, engineered proteins, and biologics bring their innovations closer to clinical or commercial success. Over a 9-month period, selected companies engage with CDL’s global network of mentors including experienced biotech founders, operators, pharmaceutical executives, angel investors, and venture capitalists. They receive strategic guidance tailored to their technical, regulatory, and business challenges. Companies are expected to identify key objectives at each program session and work toward eliminating critical risks before the next. This milestone-driven process ensures only the highest-potential companies remain in the program. CDL’s non-dilutive model—no fees and no equity taken—offers immense value, particularly for science-heavy startups navigating long and expensive development timelines. In addition to business mentorship, CDL’s Advanced Therapies stream provides access to scientific advisors from leading academic institutions and R&D-intensive companies. Ventures benefit from feedback on preclinical and clinical strategies, IP positioning, regulatory roadmaps, and partnership development. The program also enhances investor readiness by connecting companies to life sciences-focused VCs and pharma partners aligned with their stage and scientific domain.
Explore similar funding opportunities that match your goals.